13 results about "Brucella" patented technology

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

This invention provides a live attenuated Brucella vaccine strain M5Δ pyrE Its construction methods and applications belong to the field of biotechnology. The M5... pyrE The strain was obtained by knocking out Brucella mesenteriae strain M5. pyrE Genetically constructed and deposited at the China Center for Type Culture Collection. This invention discovers that... pyrE The gene is associated with Brucella virulence; knocking out this gene significantly weakens Brucella virulence and reduces its intracellular and mouse viability. Compared to the existing vaccine strain M5-9026, M5... pyrE The strain exhibits superior immunoprotective effects, effectively inducing humoral and Th1 cellular immune responses, and demonstrates good safety. The M5 strain constructed in this invention... pyrE This strain has promising potential as a candidate strain for a live attenuated vaccine to prevent brucellosis in animals.

This invention provides a primer-probe combination, reagents, methods, and applications for detecting Brucella vaccine strain RB51, belonging to the field of pathogen detection technology. The primer-probe combination for detecting Brucella vaccine strain RB51 of this invention includes a forward primer RB51-F, a reverse primer RB51-R, and a probe RB51-P; the forward primer RB51-F is shown in SEQ ID NO:1, the reverse primer RB51-R is shown in SEQ ID NO:2, and the probe RB51-P is shown in SEQ ID NO:3. The fluorescent PCR and digital PCR detection methods established based on the primer-probe combination of this invention have high sensitivity, good specificity, fast detection speed, and high throughput, enabling rapid detection of Brucella vaccine strain RB51, making differential diagnosis more accurate, economical, efficient, and convenient.

This application discloses a composition, a method for preparing the composition, and its application, comprising: an mRNA molecule containing a first sequence; and an LNP nanoparticle delivery carrier; wherein the protein encoded by the first sequence has BP26 protein immunogenicity, the first sequence encodes a first amino acid sequence, the first amino acid sequence includes multiple sub-sequences in tandem, the multiple sub-sequences being selected from the amino acid sequences corresponding to T cell and B cell recognition epitopes in wild-type BP26 protein, and the composition has high immunogenicity and high targeting against Brucella.

The application discloses an ELISA antibody detection kit for identifying Brucella gene deletion live vaccine (M5-90△26 strain) and wild strains and application. The kit comprises enzyme-linked reaction plate 1 and enzyme-linked reaction plate 2. The enzyme-linked reaction plate 1 is coated with LPS extracted from the Brucella gene deletion live vaccine (M5-90△26 strain), and the enzyme-linked reaction plate 2 is coated with a Brucella BP26 antigen epitope polypeptide combination composed of polypeptides with amino acid sequences shown in SEQ ID NO:1-2. The application is suitable for goats and sheep inoculated with the Brucella gene deletion live vaccine (M5-90△26 strain), can effectively distinguish the antibody produced by the Brucella gene deletion live vaccine (M5-90△26 strain) and the antibody produced by wild strain infection, thereby realizing identification and detection, being favorable for prevention and control of brucellosis and optimization of a vaccination strategy, and providing technical support for healthy and sustainable development of animal husbandry.

This invention belongs to the field of bioengineering technology, specifically relating to a Brucella OMP16 B-cell epitope fusion protein and its applications. The fusion protein comprises multiple repeating units linked by flexible linking peptides. Each repeating unit is formed by the tandem sequence of five Brucella OMP16 B-cell epitopes in their native order; the amino acid sequences of the five B-cell epitopes are: TLSKQAQW, LQRYPQY, GQRRAAAT, RDFLASRG, and VPTNRMRT. Based on this, this invention screened for the fusion protein with the best structural stability and theoretical solubility. It strongly binds to Brucella whole-cell polyclonal antibodies and OMP16 polyclonal antibodies, and is specifically recognized by five corresponding OMP16 monoclonal antibodies, indicating that the flexible linking peptides and tandem sequence effectively maintain the native conformation and spatial accessibility of each B-cell epitope.

This invention belongs to the field of microbial technology, specifically relating to a Brucella-deficient strain 104MΔBioZ, its construction method, and its applications. The Brucella-deficient strain 104MΔBioZ is formed by knocking out a gene involved in biotin synthesis in the Brucella 104M genome. BioZ The strain obtained after gene sequencing; the strain involved in biotin synthesis BioZ The nucleotide sequence of the gene is shown in SEQ ID NO:1. This invention utilizes the knockout of biotin synthesis in Brucella 104M. BioZ A mutant strain was obtained through gene synthesis. The resulting mutant strain exhibited significantly reduced virulence compared to Brucella 104M and demonstrated highly effective resistance to infection by the parent Brucella. Results showed that immunizing healthy mice with the 104MΔBioZ strain described in this invention for brucellosis prevention is safe and provides high protection. The Brucella-deficient strain 104MΔBioZ has broad application prospects in the field of brucellosis prevention and control.

The application discloses a fever-reducing traditional Chinese medicine decoction for treating acute fever of brucellosis, and relates to the technical field of traditional Chinese medicine.The decoction is composed of 15 kinds of traditional Chinese medicine decoction pieces, i.e., radix bupleuri, radix scrophulariae, radix paeoniae rubra, radix paeoniae alba, radix scrophulariae, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae alba, radix paeoniae

This invention provides a brucellosis benzalkonium chloride agglutination test plate, comprising a plate body with detection slots for holding the test solution. Each detection slot includes a bottom surface, an inclined surface, and an arc surface. The angle between the inclined surface and the vertical plane is 23.5°, and the angle between the bottom surface and the inclined surface is 113.5°. A groove is provided at the bottom of the plate body. There are twenty-four detection slots. The plate body is made of highly transparent PMMA material. This invention can replace traditional glass slides in the benzalkonium chloride agglutination test. It is safe, efficient, and easy to use, with high transparency. The liquid spreads evenly within the wells without external force, meeting national standards and contributing to clear test results with distinct positive and negative results. It is suitable for manual testing and compatible with various instruments and equipment. The PMMA raw material has sufficient stability and corrosion resistance, ensuring that the reagents and samples are not affected by the material properties, thus preventing the results from being affected.

The application relates to the technical field of artificial intelligence. A method and system for intelligent risk assessment of brucellosis in a large-scale dairy farm are provided, wherein the method comprises the following steps: collecting multi-source heterogeneous proxy data related to biological safety regulation execution through Internet of Things terminals and visual sensing devices deployed in key areas of the dairy farm; performing computer vision behavior recognition and process mining on the multi-source heterogeneous proxy data to obtain dynamic quantitative indexes of biological safety compliance; performing multi-source data fusion on the dynamic quantitative indexes of biological safety compliance to obtain a biological safety compliance index BCI; and injecting the biological safety compliance index BCI as a time-varying risk weight into a preset brucellosis transmission model to generate a dynamic risk assessment result fused with human risk, so that the technical effects of improving dynamic capture capability of human risk, enhancing multi-source data fusion accuracy and improving real-time risk assessment are achieved.

This invention belongs to the field of biomedical technology, specifically relating to a kit for detecting brucellosis and its application. The kit includes an enzyme-linked immunosorbent assay (ELISA) plate coated with a capture antibody, HRP-labeled antibody, antigen standards, washing buffer, chromogenic solution, and stop solution. The heavy chain amino acid sequence of the anti-CTSC protein monoclonal antibody CTSC-1 in the capture antibody is shown in SEQ ID NO.1, and the light chain amino acid sequence is shown in SEQ ID NO.2. The heavy chain amino acid sequence of the anti-CTSC protein monoclonal antibody CTSC-2 in the HRP-labeled antibody is shown in SEQ ID NO.3, and the light chain amino acid sequence is shown in SEQ ID NO.4. The kit for detecting brucellosis provided by this invention has high specificity, can specifically detect the content of CTSC protein in urine, has high sensitivity, and has good application prospects.

The application discloses a kind of detection anti-Brucella antibody multi-link B cell epitope recombinant protein and its application, it belongs to the field of biotechnology and immunodiagnosis technique, wherein, multi-link B cell epitope recombinant protein is formed by the B cell epitope of seven key outer membrane proteins Omp10, Omp16, Omp19, Omp25, Omp31, Omp2b, BP26 of Brucella, its amino acid sequence is as shown in sequence table SEQ ID NO:1.The multi-link B cell epitope recombinant protein has good antigenicity and reactivity, and the deer serum indirect ELISA detection system established with it as coating antigen shows excellent detection performance, has high sensitivity, strong specificity and good repeatability, and can accurately detect the level of anti-Brucella antibody in deer serum sample.

This invention discloses a method for preparing Brucella antibodies, relating to the field of Brucella antibody preparation technology. Based on one or more combinations of Brucella outer membrane proteins Omp10, Omp19, and BP26, a recombinant antigen is prepared, and the prokaryotic expression codon is optimized. Alpacas are immunized subcutaneously with the recombinant antigen and adjuvant at multiple sites, with booster injections every two weeks for three weeks, to isolate highly active lymphocytes. Total RNA is extracted from the lymphocytes, reverse transcribed to synthesize cDNA, and the VHH gene is specifically amplified by nested PCR to accurately obtain the antibody coding sequence. The VHH gene is cloned into a phage vector, and a high-capacity display library is constructed by electroporation. Solid-phase panning is performed using the recombinant antigen as a target, followed by sequencing to construct a prokaryotic expression vector. Recombinant nanobodies are induced to express, purified by affinity chromatography, and elution conditions are optimized to obtain high-purity, high-yield target proteins. The optimized prokaryotic expression and purification process results in nanobodies with high soluble expression rate, high purification yield, and stable activity, achieving large-scale, low-cost preparation.